Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats

Brain Res. 2005 Jan 21;1031(2):202-10. doi: 10.1016/j.brainres.2004.10.038.

Abstract

Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress. In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats. Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days caused a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching, compared to the control. Haloperidol administration (one dose of 12 mg/kg once a week s.c.) for 4 weeks caused an increase in vacuous chewing, tongue protrusion and duration of facial twitching observed in four weekly evaluations. After the treatments and behavioral observation, glutamate uptake by segments of the brain was analyzed. A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control. Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia. These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents
  • Brain / metabolism*
  • Disease Models, Animal
  • Drug Administration Schedule
  • Dyskinesia, Drug-Induced / metabolism*
  • Glutamic Acid / pharmacokinetics*
  • Haloperidol
  • Male
  • Mastication / physiology*
  • Rats
  • Rats, Wistar
  • Reserpine
  • Synaptosomes / metabolism*
  • Tongue

Substances

  • Antipsychotic Agents
  • Glutamic Acid
  • Reserpine
  • Haloperidol